Hormone dependency of breast cancer
β Scribed by Elwood V. Jensen
- Publisher
- John Wiley and Sons
- Year
- 1981
- Tongue
- English
- Weight
- 682 KB
- Volume
- 47
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
Quantitative determination of the estrogen receptor (estrophilin) content of a n excised tumor specimen provides information useful in selecting the type of systemic therapy best suited to the individual patient with advanced breast cancer. Women whose tumors contain low or negligible amounts of estrophilin rarely respond to endocrine ablation or other hormone therapy, whereas most but not all patients with receptor-rich cancers receive benefit from endocrine treatment. Properly interpreted, estrophilin assay predicts hormone dependency correctly in 85 to 90 percent of the cases. Analysis of the primary tumor at the time of mastectomy not only serves as a guide to subsequent therapy if metastases should appear but it also provides a clue to the probability and rapidity of recurrence.
Because present methods for receptor determination have certain limitations, we are developing an immunoassay, based on monoclonal antibodies to human estrophilin, that promises to provide a simple, inexpensive procedure for the routine analysis of breast cancer specimens.
π SIMILAR VOLUMES
The translocatable receptors categorized as functional receptors were quantitated in a cross-incubation study of breast cancer nuclei with receptor-rich uterine cytosol. Data demonstrated that tumors that contained cytosolic estrogen receptor (ER) but had translocation defect might not be hormone de
Serum melatonin was determined over 24 hours in 35 patients with breast cancer with either a fresh primary tumor (n = 23) or a secondary tumor (n = 12) and in 28 patients with untreated benign breast disease (controls) having a fibroadenoma (n = lo), fibrocystic mastopathy (n = 14), or other breast
## Abstract Oestradiol (E2) stimulates the growth of hormoneβdependent breast cancer. 17Ξ²βhydroxysteroid dehydrogenases (17Ξ²βHSDs) catalyse the preβreceptor activation/inactivation of hormones and other substrates. 17Ξ²βHSD1 converts oestrone (E1) to active E2, but it has recently been suggested tha